March 28, 2017 11:47 PM ET

Pharmaceuticals

Company Overview of F2G Ltd

Company Overview

F2G Ltd. discovers and develops novel drugs to treat life threatening fungal diseases. It primarily focuses on developing an F3 series of anti-mold compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company offers orotomides that are active against Aspergillus and other filamentous molds. F2G Ltd. was founded in 1998 and is based in Manchester, United Kingdom.

Lankro Way

Eccles

Manchester,  M30 0LX

United Kingdom

Founded in 1998

Phone:

44 1617 851 270

Fax:

44 1617 851 273

Key Executives for F2G Ltd

Chief Executive Officer and Executive Director
Age: 55
Chief Financial Officer
Age: 49
Chief Operating Officer
Chief Medical Officer and Director
Non-Executive Chairman and Member of Management Board
Age: 73
Compensation as of Fiscal Year 2016.

F2G Ltd Key Developments

F2G Ltd Appoints John Rex as Chief Medical Officer

F2G Ltd. has announced the appointment of John Rex as chief medical officer. Rex is a distinguished research scientist and a key opinion leader in the field of infectious disease therapy, in particular antifungal agents. He held the position of Senior vice president and Head of Infection, Global Medicines Development at AstraZeneca until October 2016.

F2G Ltd Presents at Biotech and Money Inv€$tival Showcase, Nov-18-2016 10:30 AM

F2G Ltd Presents at Biotech and Money Inv€$tival Showcase, Nov-18-2016 10:30 AM. Venue: The Waldorf Hilton Hotel, Aldwych, London, WC2 4DD, United Kingdom.

F2G Ltd Announces the Appointment of Ralf Schmid as Chief Financial Officer

F2G Ltd. announced the appointment of Ralf Schmid to the position of Chief Financial Officer, effective from 4thJuly 2016. Ralf brings over 20 years' experience to F2G, with considerable expertise in M&A, licensing, public and private market transactions. Ralf Schmid joins F2G from Nabriva Theraputics AG, where he served on the management board since the company's inception in 2006. In his role as Chief Financial and Chief Operating Officer, Ralf was instrumental in taking the company public on NASDAQ in September 2015. He has held various senior positions in finance and administration at several multi-national companies including Sandoz where he led the spin-off of Nabriva.

Similar Private Companies By Industry

Company Name Region
Abbey Pharma Limited Europe
Absynth Biologics Limited Europe
Acacia Pharma Limited Europe
AccentBio Ltd. Europe
Aclar Limited Europe

Recent Private Companies Transactions

Type
Date
Target
Private Placement
June 20, 2016
--
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact F2G Ltd, please visit www.f2g.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.